Citations 1
Phase II study of nab-paclitaxel/gemcitabine (NabP-Gem) alternating with FOLFIRI as 1st line therapy ( Rx) in patients (pts) with metastatic pancreatic cancer (mPC).
Picozzi, Vincent J. , Leach, Joseph L., Larson, Tim , Nishikubo, Carol Y., Anthony, Stephen P. , Lin, Bruce, Stoll, Amy C., Hoff, Daniel D. Von , Ramanathan, Ramesh K., Leach, Joseph, Larson, Tim, Bolejack, Vanessa
Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e15277-e15277
